HDA UK Media And Political Bulletin – 16 March 2017

Media Summary

March 2017 Price Concessions
PSNC, 15 March 2017

The Department of Health have granted the following price concessions for March 2017:

Drug Pack size Price concession
Amitriptyline 50mg tablets 28 £3.50
Dapsone 50mg tablets 28 £46.19
Exemestane 25mg tablets 30 £12.60
Flecainide 100mg  tablets 60 £16.53
Flecainide 50mg  tablets 60 £11.57
Glibenclamide 5mg tablets 28 £2.49
Lorazepam 1mg tablets 28 £6.00
Mirtazapine 15mg tablets 28 £5.95
Mirtazapine 30mg tablets 28 £1.61
Mirtazapine 45mg tablets 28 £5.95
Naratriptan 2.5mg tablets 6 £23.00
Nitrofurantoin 50mg tablets 28 £20.50
Oxazepam 10mg tablets 28 £7.97
Oxazepam 15mg tablets 28 £7.75
Ropinirole 1mg tablets 84 £56.71
Ropinirole 5mg tablets 84 £165.00
Spironolactone 50mg tablets 28 £5.20
Valsartan 160mg capsules 28 £17.65
Valsartan 40mg capsules 28 £8.95
Valsartan 80mg capsules 28 £11.99
Zolmitriptan 2.5mg orodispersible tablets sugar free 6 £15.22
Zolmitriptan 2.5mg tablets 6 £15.30

No endorsements are required as these prices will automatically be applied to this month’s prescriptions.

New UK drug cost rules leave companies fuming
Reuters, Ben Hirschler, 15 March 2017

British drug-makers have said the government is breaking a manifesto commitment to improve access to new medicines, following approval of new cost rules that take effect on April 1. The changes are meant to introduce a new fast-track option for appraising treatments which offer exceptional value for money. Some charities also expressed concern that the measures could mean delays for people with serious conditions in getting new treatments. Drug companies are already concerned that Brexit could make Britain a less attractive market. However, the National Institute for Health and Care Excellence (NICE) and NHS England say the new procedures will fast-track the availability of drugs that offer exceptional value. Significantly, the new rules apply only to England, leaving a different system in place for Scotland.

The European Pharmaceutical Review also reports on the new fast-track option.

Parliamentary Coverage

There is no Parliamentary Coverage.

Full Coverage

New UK drug cost rules leave companies fuming
Reuters, Ben Hirschler, 15 March 2017

British drugmakers on Wednesday accused Theresa May’s Conservative government of breaking a manifesto commitment to improve access to new medicines, following approval of new cost rules that take effect on April 1.

The angry response from both Big Pharma and biotech firms comes despite a concession by government in the latest version of the scheme, which increases the cost threshold for certain drugs for rare diseases from the previously planned level.

Some charities, including the Alzheimer’s Society, also expressed concern that the measures could mean delays for people with serious conditions in getting new treatments.

The row comes at a sensitive time for the government, which is about to trigger proceedings to leave the European Union but wants to encourage investment by strategic industries, including the high-tech pharmaceuticals sector.

Drug companies are already concerned that Brexit could make Britain a less attractive market, especially if the country ends up outside the current EU-wide system for drug licensing.

The National Institute for Health and Care Excellence (NICE), which determines the cost-effectiveness of new drugs, and NHS England say their new procedures will fast-track the availability of drugs that offer exceptional value.

From Factory to Pharmacy

As part of our mission to build awareness, understanding and appreciation of the vital importance of the healthcare distribution sector, we developed an infographic explaining the availability of medicines. It identifies the factors that can impact drug supply, as well as the measures that HDA members undertake day in, day out to help mitigate the risks of patients not receiving their medicines.

See the Infographic

Apply to become a Member

Membership of the HDA guarantees your organisation:

  • Access to leading policy and industry forums of debate and discussion
  • Invitations to a range of networking industry events organised through the year, including an Annual Conference and a Business Day
  • Representation on HDA working parties, including the Members’ Liaison Group
  • A daily Political and Media Bulletin and HDA Newsletters
  • Access to HDA policy documents and all sections of the HDA website
  • Branding and marketing opportunities
Apply Now

Already a Member?